Every reporter: Cai Ding Every editor: Wu Yongjiu
In the early morning of June 15th, Beijing time, LinkDoc Technology Limited, a Chinese medical big data company, submitted its first F-1 prospectus to the U.S. Securities and Exchange Commission (SEC). The company plans to be listed on the Nasdaq Global Select Market. Listed under the trading code “LDOC” and raised US$100 million. The underwriters of ZeroKr Technology’s IPO are Morgan Stanley, Bank of America Securities and CICC. Since it is the first F-1 prospectus, LingKr Technology has not yet disclosed the number of American Depositary Shares (ADS) to be issued and the expected issuance price range.
The prospectus shows that Zerokrypton Technology intends to use IPO funds raised: about 45% will be used to strengthen R&D capabilities and technical infrastructure, and to attract more oncologists, data scientists and other experienced professionals to join; about 15% will be used for expansion The company’s patient care center network and services, and other capital expenditures; about 25% of the funds will be used for potential strategic investments and acquisitions; about 15% will be used for general corporate purposes.
Visual China Map
Obtained strategic investment from Alibaba Health
According to the prospectus, Zerokrypton Technology was established in 2014, headquartered in Beijing, China, and its corporate address is No. 8 Haidian Street, Haidian District, Beijing. The company is a tumor big data solution provider. In March this year, it received a strategic investment from Ali Health. Other investors include China Investment Corporation and CICC Capital.
The prospectus quoted Frost&Sullivan’s data as saying that in terms of cultivating high-quality medical data assets, ZeroKrypton Technology is a leading data-driven and artificial intelligence medical technology company. The company has established China’s largest data-driven digital infrastructure for precision medicine. These include LinkCare, a digital continuous care platform for critically ill patients, LinkData, a longitudinal medical data management system that supports artificial intelligence, and LinkSolutions, a data-driven precision life science solution platform that helps life science companies accelerate clinical research and real evidence adoption.
According to the prospectus, in terms of the nursing platform LinkCare, Lingkrypton Technology generates revenue by selling innovative drugs, auxiliary drugs and nutritional drugs, as well as providing patients with infusion or injection services and other auxiliary businesses; LinkData is the core technology of Lingkrypton Technology. Platforms and R&D engines, not profit channels; LinkSolutions is a platform driven by real-world data, providing accurate life science solutions for life science companies in their clinical and commercialization stages. In the first quarter of 2021, the number of life science company customers of ZeroKr Technology was 169. As of March 31, 2021, LinkSolutions Service of LinkSolutions has supported more than 310 major researchers, covering approximately of the total number of new oncology indications approved for clinical trials in China from 2017 to March 31, 2021. 57%. Specifically, Zerokrypton Technology realizes the monetization of LinkSolutions by charging service fees for comprehensive clinical research services.
The prospectus shows that the vast majority of Zerokrypton Technology’s revenue comes from the sales of medicines and health products. The sales revenue of medicines and health products accounted for 75% and 85.5% of the company’s total revenue in 2019 and 2020, respectively, and accounted for 80.2% of the total revenue in the first quarter of 2021.
The prospectus shows that since April 2015, LingKr Technology has provided care for more than 3.5 million patients and provided longitudinal care for more than 2.5 million patients. According to Frost & Sullivan, Zero Krypton Technology has become China’s largest patient-centered continuous tumor care platform. As of March 31, 2021, ZeroKr Technology has established 34 patient care centers nationwide, covering 28 provinces across the country.
The prospectus shows that in 2019 and 2020, Zerokrypton Technology’s revenue will be 499 million yuan and 942 million yuan, net losses will be 434 million yuan and 489 million yuan, and basic and diluted losses per share will be 5.32 yuan and 6.59 yuan respectively. In the first quarter of 2021, the company’s revenue increased by 41% year-on-year to 223 million yuan, a net loss of 138 million yuan, and a basic and diluted loss per share of 1.76 yuan.
Completed six rounds of financing since its establishment
Zerokrypton Technology stated in its prospectus that, based on 2019 data, China is the world’s second largest medical market, with national medical expenditures of US$944 billion, an increase of 9.7% over 2015. With the improvement of people’s health awareness and personal disposable income, China’s total healthcare expenditure is expected to increase to US$2.529 billion at a compound annual growth rate of 9.4% in 2030. The total scale of China’s medical big data solutions market is rapidly growing at a compound annual growth rate of 43.9% from US$1 billion in 2015 to US$4.1 billion in 2019. It is expected to reach US$215.4 billion in 2030. The compound annual growth rate is 43.3%.
The prospectus also stated that among all the treatment fields in China, oncology has the highest growth rate in medical expenditures, mainly because China has the largest number of cancer patients in the world. The scale of China’s oncology big data market has grown from US$500 million in 2015 to US$2.1 billion, with a compound annual growth rate of 46.1%. It is expected to grow to US$119.6 billion by 2030. The compound annual growth rate from 2019 to 2030 is 44.4%.
The prospectus shows that as of March 31, 2021, ZeroKr Technology has 1,250 full-time employees, of which 199 are responsible for technology and R&D, 573 are responsible for operation and quality assurance, 352 are responsible for sales and marketing, and 126 are responsible for general administrative work. .
According to the prospectus, before the IPO, Zhang Tianze, CEO and director of LingKr Technology, held 61.3 million shares of the company, accounting for 19.7%; LingKr Technology co-founder, COO and CTO Luo Ligang held 9 million shares, accounting for 2.9%; Technology co-founder and executive vice president Li Liping holds 11 million shares, accounting for 3.5%.
According to the information of Qixinbao, since its establishment, Lingkrypton Technology has completed a total of six rounds of financing. After obtaining 1 billion yuan in Series D financing from China Investment Corporation on July 4, 2018, it received CICC Capital and Excellent on September 7, 2020. Hill Capital and Broadband Capital CBC 700 million US dollars in financing. On March 4 this year, Zerokrypton Technology also received a strategic investment from Alibaba Health, but the amount of financing was not disclosed.
The “Daily Business News” reporter noted that Qixinbao’s risk information on ZeroKr Technology showed that the company had been accused of labor disputes and infringement of the right to disseminate information on the Internet on May 15, 2019 and November 23, 2020, respectively. Prosecute. Secondly, on September 1 and December 1, 2020, there were two civil case judgment documents against the intellectual property rights infringement disputes of Zerokrypton Technology. The documents show that in the two dispute cases, Zerokrypton Technology is both defendant. In addition, Zhang Tianze, Li Liping and Luo Ligang all have a small amount of shares currently in a state of pledge.
Daily economic news
You must log in to post a comment.